{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:44:54Z","timestamp":1790959494733,"version":"4.1.0"},"reference-count":134,"publisher":"Portland Press Ltd.","issue":"23","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In 2020 we are celebrating the 20th anniversary of the angiotensin-converting enzyme 2 (ACE2) discovery. This event was a landmark that shaped the way that we see the renin\u2013angiotensin system (RAS) today. ACE2 is an important molecular hub that connects the RAS classical arm, formed mainly by the octapeptide angiotensin II (Ang II) and its receptor AT1, with the RAS alternative or protective arm, formed mainly by the heptapeptides Ang-(1-7) and alamandine, and their receptors, Mas and MrgD, respectively. In this work we reviewed classical and modern literature to describe how ACE2 is a critical component of the protective arm, particularly in the context of the cardiac function, coagulation homeostasis and immune system. We also review recent literature to present a critical view of the role of ACE2 and RAS in the SARS-CoV-2 pandemic.<\/jats:p>","DOI":"10.1042\/cs20200478","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T13:09:20Z","timestamp":1606914560000},"page":"3063-3078","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["ACE2 in the renin\u2013angiotensin system"],"prefix":"10.1042","volume":"134","author":[{"given":"Thiago","family":"Verano-Braga","sequence":"first","affiliation":[{"name":"National Institute of Science and Technology in Nano-Biopharmaceutics (INCT-NanoBiofar) \u2013 Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luiza\u00a0Valle","family":"Martins","sequence":"additional","affiliation":[{"name":"Hospital Mater Dei, Intensive Care Unit, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-7838","authenticated-orcid":false,"given":"Daisy","family":"Motta-Santos","sequence":"additional","affiliation":[{"name":"National Institute of Science and Technology in Nano-Biopharmaceutics (INCT-NanoBiofar) \u2013 Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9483-4206","authenticated-orcid":false,"given":"Maria\u00a0Jos\u00e9","family":"Campagnole-Santos","sequence":"additional","affiliation":[{"name":"National Institute of Science and Technology in Nano-Biopharmaceutics (INCT-NanoBiofar) \u2013 Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson\u00a0Augusto Souza","family":"Santos","sequence":"additional","affiliation":[{"name":"National Institute of Science and Technology in Nano-Biopharmaceutics (INCT-NanoBiofar) \u2013 Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"2021113011180097400_B1","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021113011180097400_B2","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"2021113011180097400_B3","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2021113011180097400_B4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/0024-3205(86)90565-5","article-title":"Biological activities of angiotensin II-(1-6)-hexapeptide and angiotensin II-(1-7)-heptapeptide in man","volume":"38","author":"Kono","year":"1986","journal-title":"Life Sci."},{"key":"2021113011180097400_B5","doi-asserted-by":"publisher","first-page":"I153","DOI":"10.1161\/01.HYP.11.2_Pt_2.I153","article-title":"Converting enzyme activity and angiotensin metabolism in the dog brainstem","volume":"11","author":"Santos","year":"1988","journal-title":"Hypertension"},{"key":"2021113011180097400_B6","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1073\/pnas.85.11.4095","article-title":"Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide","volume":"85","author":"Schiavone","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011180097400_B7","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/00005344-199016004-00006","article-title":"Angiotensin-[1-7]: evidence for novel actions in the brain","volume":"16","author":"Schiavone","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021113011180097400_B8","first-page":"H324","article-title":"Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats","volume":"257","author":"Campagnole-Santos","year":"1989","journal-title":"Am. J. Physiol."},{"key":"2021113011180097400_B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00018-009-0152-x","article-title":"Not just angiotensinases: new roles for the angiotensin-converting enzymes","volume":"67","author":"Lambert","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"2021113011180097400_B10","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011180097400_B11","doi-asserted-by":"publisher","first-page":"e13280","DOI":"10.1111\/apha.13280","article-title":"Anti-fibrotic mechanisms of angiotensin AT2 -receptor stimulation","volume":"227","author":"Sumners","year":"2019","journal-title":"Acta Physiol."},{"key":"2021113011180097400_B12","doi-asserted-by":"publisher","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","article-title":"The renin-angiotensin system: going beyond the classical paradigms","volume":"316","author":"Santos","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011180097400_B13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ. Res."},{"key":"2021113011180097400_B14","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2021113011180097400_B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"2021113011180097400_B16","doi-asserted-by":"publisher","first-page":"428950","DOI":"10.1155\/2012\/428950","article-title":"Recombinant expression and characterization of human and murine ACE2: species-specific activation of the alternative renin-angiotensin-system","volume":"2012","author":"Poglitsch","year":"2012","journal-title":"Int. J. Hypertens"},{"key":"2021113011180097400_B17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/msb.2008.61","article-title":"Selected reaction monitoring for quantitative proteomics: a tutorial","volume":"4","author":"Lange","year":"2008","journal-title":"Mol. Syst. Biol."},{"key":"2021113011180097400_B18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"2021113011180097400_B19","doi-asserted-by":"publisher","first-page":"F841","DOI":"10.1152\/ajprenal.2000.279.5.F841","article-title":"Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues","volume":"279","author":"Allred","year":"2000","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021113011180097400_B20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/01.HYP.19.6.692","article-title":"In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats","volume":"19","author":"Yamamoto","year":"1992","journal-title":"Hypertension"},{"key":"2021113011180097400_B21","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cphy.c120002","article-title":"Nonclassical renin-angiotensin system and renal function","volume":"2","author":"Chappell","year":"2012","journal-title":"Compr. Physiol."},{"key":"2021113011180097400_B22","doi-asserted-by":"publisher","first-page":"II56","DOI":"10.1161\/01.HYP.19.2_Suppl.II56","article-title":"Production of angiotensin-(1-7) by human vascular endothelium","volume":"19","author":"Santos","year":"1992","journal-title":"Hypertension"},{"key":"2021113011180097400_B23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (Angiotensin II) conversion to Angiotensin-(1-7) in the circulation is POP (Prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"2021113011180097400_B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","article-title":"Mass-spectrometric identification of a novel angiotensin peptide in human plasma","volume":"27","author":"Jankowski","year":"2007","journal-title":"Arteriosclerosis Thromb. Vasc. Biol."},{"key":"2021113011180097400_B25","doi-asserted-by":"publisher","first-page":"110038","DOI":"10.1016\/j.mehy.2020.110038","article-title":"The possible role of a bacterial aspartate beta-decarboxylase in the biosynthesis of alamandine","volume":"144","author":"Jha","year":"2020","journal-title":"Med. Hypotheses"},{"key":"2021113011180097400_B26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents","volume":"51","author":"Hernandez Prada","year":"2008","journal-title":"Hypertension"},{"key":"2021113011180097400_B27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/1087057111413919","article-title":"Prediction of off-target effects on angiotensin-converting enzyme 2","volume":"16","author":"Kulemina","year":"2011","journal-title":"J. Biomol. Screen."},{"key":"2021113011180097400_B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.regpep.2012.05.093","article-title":"Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction","volume":"177","author":"Murca","year":"2012","journal-title":"Regul. Pept."},{"key":"2021113011180097400_B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1113\/expphysiol.2010.055277","article-title":"Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases","volume":"96","author":"Ferreira","year":"2011","journal-title":"Exp. Physiol."},{"key":"2021113011180097400_B30","doi-asserted-by":"publisher","first-page":"H1697","DOI":"10.1152\/ajpheart.00854.2014","article-title":"ACE2\/Ang-(1-7)\/Mas axis stimulates vascular repair-relevant functions of CD34+ cells","volume":"309","author":"Singh","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011180097400_B31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2119\/molmed.2009.00160","article-title":"ACE2 activation promotes antithrombotic activity","volume":"16","author":"Fraga-Silva","year":"2010","journal-title":"Mol. Med."},{"key":"2021113011180097400_B32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"2021113011180097400_B33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.biopha.2018.07.170","article-title":"The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats","volume":"107","author":"Castardeli","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"2021113011180097400_B34","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/ars.2014.6070","article-title":"Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes","volume":"23","author":"Zhang","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"2021113011180097400_B35","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1111\/bph.13946","article-title":"Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes","volume":"174","author":"Goru","year":"2017","journal-title":"Br J. Pharmacol."},{"key":"2021113011180097400_B36","doi-asserted-by":"publisher","first-page":"10175","DOI":"10.1038\/s41598-018-28490-y","article-title":"The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice","volume":"8","author":"Rajapaksha","year":"2018","journal-title":"Sci. Rep."},{"key":"2021113011180097400_B37","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.npep.2020.102076","article-title":"Angiotensin-converting enzyme 2 activator, DIZE in the basolateral amygdala attenuates the tachycardic response to acute stress by modulating glutamatergic tone","volume":"83","author":"Silva","year":"2020","journal-title":"Neuropeptides"},{"key":"2021113011180097400_B38","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/HYPERTENSIONAHA.113.02856","article-title":"Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro","volume":"63","author":"Haber","year":"2014","journal-title":"Hypertension"},{"key":"2021113011180097400_B39","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/1440-1681.13368","article-title":"Acute hypotensive effect of diminazene aceturate in spontaneously hypertensive rats: role of NO and Mas receptor","volume":"47","author":"Sartorio","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2021113011180097400_B40","doi-asserted-by":"publisher","first-page":"103486","DOI":"10.1016\/j.jprot.2019.103486","article-title":"Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4","volume":"208","author":"Gomez-Mendoza","year":"2019","journal-title":"J. Proteomics"},{"key":"2021113011180097400_B41","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1161\/CIRCRESAHA.112.268029","article-title":"Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II\/AT1 receptor axis","volume":"110","author":"Patel","year":"2012","journal-title":"Circ. Res."},{"key":"2021113011180097400_B42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","article-title":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice","volume":"97","author":"Wang","year":"2016","journal-title":"J. Mol. Cell Cardiol."},{"key":"2021113011180097400_B43","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/01.HYP.0000215289.51180.5c","article-title":"Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice","volume":"47","author":"Santos","year":"2006","journal-title":"Hypertension"},{"key":"2021113011180097400_B44","doi-asserted-by":"publisher","first-page":"H459","DOI":"10.1152\/ajpheart.00498.2016","article-title":"Differential effects of Mas receptor deficiency on cardiac function and blood pressure in obese male and female mice","volume":"312","author":"Wang","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011180097400_B45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.lfs.2006.09.007","article-title":"Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during ischemia\/reperfusion in the isolated perfused mouse heart","volume":"80","author":"Castro","year":"2006","journal-title":"Life Sci."},{"key":"2021113011180097400_B46","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/cvr\/cvaa078","article-title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2","volume":"116","author":"Chen","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"2021113011180097400_B47","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"2021113011180097400_B48","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1172\/JCI16980","article-title":"Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice","volume":"116","author":"Gurley","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2021113011180097400_B49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.HYP.0000205833.89478.5b","article-title":"Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II","volume":"47","author":"Yamamoto","year":"2006","journal-title":"Hypertension"},{"key":"2021113011180097400_B50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/hr.2016.28","article-title":"Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise","volume":"39","author":"Motta-Santos","year":"2016","journal-title":"Hypertens. Res."},{"key":"2021113011180097400_B51","doi-asserted-by":"publisher","first-page":"271.e278","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"2021113011180097400_B52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"2021113011180097400_B53","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0022-2828(03)00177-9","article-title":"Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins","volume":"35","author":"Donoghue","year":"2003","journal-title":"J. Mol. Cell Cardiol."},{"key":"2021113011180097400_B54","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1152\/physiolgenomics.00227.2003","article-title":"Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats","volume":"17","author":"Santos","year":"2004","journal-title":"Physiol. Genomics"},{"key":"2021113011180097400_B55","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.184911","article-title":"Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart","volume":"103","author":"Mercure","year":"2008","journal-title":"Circ. Res."},{"key":"2021113011180097400_B56","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00109-015-1285-z","article-title":"Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2","volume":"93","author":"Patel","year":"2015","journal-title":"J. Mol. Med. (Berl.)"},{"key":"2021113011180097400_B57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"2021113011180097400_B58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.phrs.2008.12.008","article-title":"Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats","volume":"59","author":"Al-Maghrebi","year":"2009","journal-title":"Pharmacol. Res."},{"key":"2021113011180097400_B59","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.4049\/jimmunol.1000314","article-title":"Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis","volume":"185","author":"da Silveira","year":"2010","journal-title":"J. Immunol."},{"key":"2021113011180097400_B60","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1161\/CIRCRESAHA.110.219279","article-title":"Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse","volume":"107","author":"Thomas","year":"2010","journal-title":"Circ. Res."},{"key":"2021113011180097400_B61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2337\/db15-0399","article-title":"ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity","volume":"65","author":"Patel","year":"2016","journal-title":"Diabetes"},{"key":"2021113011180097400_B62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12967-015-0616-8","article-title":"Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling","volume":"13","author":"Jin","year":"2015","journal-title":"J. Transl. Med."},{"key":"2021113011180097400_B63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00011-015-0805-1","article-title":"ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response","volume":"64","author":"Zhang","year":"2015","journal-title":"Inflamm. Res."},{"key":"2021113011180097400_B64","doi-asserted-by":"publisher","first-page":"104350","DOI":"10.1016\/j.yexmp.2019.104350","article-title":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway","volume":"113","author":"Ye","year":"2020","journal-title":"Exp. Mol. Pathol."},{"key":"2021113011180097400_B65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.metabol.2019.03.006","article-title":"Angiotensin-(1-7), adipokines and inflammation","volume":"95","author":"Lelis","year":"2019","journal-title":"Metabolism"},{"key":"2021113011180097400_B66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11906-014-0512-2","article-title":"Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke","volume":"17","author":"Bennion","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"2021113011180097400_B67","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/CS20130324","article-title":"Cerebroprotective action of angiotensin peptides in stroke","volume":"126","author":"Regenhardt","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011180097400_B68","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"2021113011180097400_B69","doi-asserted-by":"publisher","first-page":"eaax9198","DOI":"10.1126\/science.aax9198","article-title":"A genome-wide transcriptomic analysis of protein-coding genes in human blood cells","volume":"366","author":"Uhlen","year":"2019","journal-title":"Science"},{"key":"2021113011180097400_B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-10010-z","article-title":"SARS-CoV-2 entry Receptor ACE2 is expressed on very small CD45(-) precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 inflammasome","author":"Ratajczak","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"2021113011180097400_B71","first-page":"419","article-title":"Prothrombotic effects of angiotensin","volume":"45","author":"Brown","year":"2000","journal-title":"Adv. Intern. Med."},{"key":"2021113011180097400_B72","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.110.158220","article-title":"Angiotensin II-mediated microvascular thrombosis","volume":"56","author":"Senchenkova","year":"2010","journal-title":"Hypertension"},{"key":"2021113011180097400_B73","doi-asserted-by":"publisher","first-page":"L17","DOI":"10.1152\/ajplung.00498.2016","article-title":"Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin\/BKB1R axis and facilitates LPS-induced neutrophil infiltration","volume":"314","author":"Sodhi","year":"2018","journal-title":"Am. J. Physiol. Lung. Cell. Mol. Physiol."},{"key":"2021113011180097400_B74","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"2021113011180097400_B75","first-page":"571","article-title":"Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats","volume":"56","author":"Kaminska","year":"2005","journal-title":"J. Physiol. Pharmacol."},{"key":"2021113011180097400_B76","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/00005344-200104000-00007","article-title":"Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan","volume":"37","author":"Jimenez","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021113011180097400_B77","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/HYPERTENSIONAHA.112.198465","article-title":"Leukocyte-dependent responses of the microvasculature to chronic angiotensin II exposure","volume":"60","author":"Yildirim","year":"2012","journal-title":"Hypertension"},{"key":"2021113011180097400_B78","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1055\/s-0038-1656136","article-title":"Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells","volume":"77","author":"Nishimura","year":"1997","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B79","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/01.CIR.90.1.362","article-title":"Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells","volume":"90","author":"van Leeuwen","year":"1994","journal-title":"Circulation"},{"key":"2021113011180097400_B80","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000190273","article-title":"Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells","volume":"77","author":"Wilson","year":"1997","journal-title":"Nephron"},{"key":"2021113011180097400_B81","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/01.CIR.87.6.1969","article-title":"Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function","volume":"87","author":"Ridker","year":"1993","journal-title":"Circulation"},{"key":"2021113011180097400_B82","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1055\/s-0037-1614864","article-title":"The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells","volume":"82","author":"Nishimura","year":"1999","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00001721-200011010-00007","article-title":"Platelet activation during angiotensin II infusion in healthy volunteers","volume":"11","author":"Larsson","year":"2000","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"2021113011180097400_B84","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF01900409","article-title":"The effect o angiotensin II on the platelet aggregation induced by adenosine diphosphate, epinephrine and thrombin","volume":"26","author":"Poplawski","year":"1970","journal-title":"Experientia"},{"key":"2021113011180097400_B85","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1055\/s-0038-1660105","article-title":"Potentiation of adrenaline-induced platelet aggregation by angiotensin II","volume":"54","author":"Ding","year":"1985","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0038-1645692","article-title":"Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects","volume":"63","author":"Swartz","year":"1990","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B87","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.jhh.1001102","article-title":"Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan","volume":"14","author":"Jagroop","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"2021113011180097400_B88","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1160\/TH04-10-0701","article-title":"Angiotensin II enhances thrombosis development in renovascular hypertensive rats","volume":"93","author":"Mogielnicki","year":"2005","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B89","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/01.RES.0000182677.89816.38","article-title":"Complement activation in angiotensin II-induced organ damage","volume":"97","author":"Shagdarsuren","year":"2005","journal-title":"Circ. Res."},{"key":"2021113011180097400_B90","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/HYPERTENSIONAHA.118.11210","article-title":"Role of complement-related inflammation and vascular dysfunction in hypertension","volume":"73","author":"Ruan","year":"2019","journal-title":"Hypertension"},{"key":"2021113011180097400_B91","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1096\/fj.201701068R","article-title":"A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation","volume":"32","author":"Senchenkova","year":"2018","journal-title":"FASEB J."},{"key":"2021113011180097400_B92","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1182\/blood.V90.10.3819","article-title":"Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes","volume":"90","author":"Colman","year":"1997","journal-title":"Blood"},{"key":"2021113011180097400_B93","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J. Exp. Med."},{"key":"2021113011180097400_B94","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1182\/blood-2007-06-092338","article-title":"Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis","volume":"111","author":"Merkulov","year":"2008","journal-title":"Blood"},{"key":"2021113011180097400_B95","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1721727X15577736","article-title":"A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes","volume":"13","author":"Tidjane","year":"2015","journal-title":"Eur. J. Inflamm."},{"key":"2021113011180097400_B96","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2014-01-550285","article-title":"Reduced thrombosis in Klkb1-\/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor","volume":"125","author":"Stavrou","year":"2015","journal-title":"Blood"},{"key":"2021113011180097400_B97","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MOH.0000000000000271","article-title":"Antithrombotic potential of the contact activation pathway","volume":"23","author":"Schmaier","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"2021113011180097400_B98","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2015-01-622811","article-title":"The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis","volume":"126","author":"Nickel","year":"2015","journal-title":"Blood"},{"key":"2021113011180097400_B99","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.thromres.2016.02.020","article-title":"A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation","volume":"140","author":"Kokoye","year":"2016","journal-title":"Thromb. Res."},{"key":"2021113011180097400_B100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1515\/BC.2001.014","article-title":"Altered neutrophil homeostasis in kinin B1 receptor-deficient mice","volume":"382","author":"Araujo","year":"2001","journal-title":"Biol. Chem."},{"key":"2021113011180097400_B101","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1160\/TH06-03-0128","article-title":"Plasma levels of bradykinin are suppressed in factor XII-deficient mice","volume":"95","author":"Iwaki","year":"2006","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B102","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1161\/CIRCULATIONAHA.112.097295","article-title":"Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner","volume":"126","author":"Barbieri","year":"2012","journal-title":"Circulation"},{"key":"2021113011180097400_B103","doi-asserted-by":"publisher","first-page":"132ra154","DOI":"10.1126\/scitranslmed.3003787","article-title":"Vascular COX-2 modulates blood pressure and thrombosis in mice","volume":"4","author":"Yu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2021113011180097400_B104","doi-asserted-by":"publisher","first-page":"17962","DOI":"10.1074\/jbc.M106101200","article-title":"Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator","volume":"277","author":"Shariat-Madar","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2021113011180097400_B105","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2012-10-460360","article-title":"Prolylcarboxypeptidase promotes angiogenesis and vascular repair","volume":"122","author":"Adams","year":"2013","journal-title":"Blood"},{"key":"2021113011180097400_B106","first-page":"61","article-title":"A novel antithrombotic mechanism mediated by the receptors of the kallikrein\/kinin and renin-angiotensin systems","volume":"3","author":"Schmaier","year":"2016","journal-title":"Front. Med. (Lausanne)"},{"key":"2021113011180097400_B107","doi-asserted-by":"publisher","first-page":"105096","DOI":"10.1016\/j.phrs.2020.105096","article-title":"Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein\/kinin and the renin-angiotensin systems","volume":"160","author":"Fang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"2021113011180097400_B108","first-page":"171","article-title":"High-affinity binding of peptide agonists to the human B1 bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor","volume":"57","author":"Fathy","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"2021113011180097400_B109","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/STROKEAHA.108.526673","article-title":"Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema","volume":"40","author":"Austinat","year":"2009","journal-title":"Stroke"},{"key":"2021113011180097400_B110","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/jcbfm.2010.28","article-title":"Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation","volume":"30","author":"Raslan","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2021113011180097400_B111","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaut.2010.11.004","article-title":"Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking","volume":"36","author":"Gobel","year":"2011","journal-title":"J. Autoimmun."},{"key":"2021113011180097400_B112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10565-009-9148-4","article-title":"L-carnitine modulates blood platelet oxidative stress","volume":"26","author":"Saluk-Juszczak","year":"2010","journal-title":"Cell Biol. Toxicol."},{"key":"2021113011180097400_B113","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1582-4934.2009.00992.x","article-title":"A novel pathway for receptor-mediated post-translational activation of inducible nitric oxide synthase","volume":"15","author":"Brovkovych","year":"2011","journal-title":"J. Cell Mol. Med."},{"key":"2021113011180097400_B114","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/375408a0","article-title":"Altered immune responses in mice lacking inducible nitric oxide synthase","volume":"375","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"2021113011180097400_B115","doi-asserted-by":"publisher","first-page":"H145","DOI":"10.1152\/ajpheart.00646.2007","article-title":"Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis","volume":"294","author":"Hong","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011180097400_B116","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1182\/blood-2012-09-459156","article-title":"Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-\/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation","volume":"121","author":"Fang","year":"2013","journal-title":"Blood"},{"key":"2021113011180097400_B117","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2119\/2007-00073.Fraga-Silva","article-title":"The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets","volume":"14","author":"Fraga-Silva","year":"2008","journal-title":"Mol. Med."},{"key":"2021113011180097400_B118","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/01.HYP.0000035396.27909.40","article-title":"Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7)","volume":"40","author":"Kucharewicz","year":"2002","journal-title":"Hypertension"},{"key":"2021113011180097400_B119","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/01.fjc.0000176729.51819.a6","article-title":"Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside","volume":"46","author":"Rajendran","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021113011180097400_B120","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1160\/TH12-06-0396","article-title":"The angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas receptor axis: a potential target for treating thrombotic diseases","volume":"108","author":"Fraga-Silva","year":"2012","journal-title":"Thromb. Haemost."},{"key":"2021113011180097400_B121","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3317\/jraas.2000.041","article-title":"The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan","volume":"1","author":"Kucharewicz","year":"2000","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"2021113011180097400_B122","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1590\/S1807-59322011000500021","article-title":"An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect","volume":"66","author":"Fraga-Silva","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"2021113011180097400_B123","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.HYP.0000251865.35728.2f","article-title":"Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways","volume":"49","author":"Sampaio","year":"2007","journal-title":"Hypertension"},{"key":"2021113011180097400_B124","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1291\/hypres.31.553","article-title":"Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade","volume":"31","author":"Igase","year":"2008","journal-title":"Hypertens. Res."},{"key":"2021113011180097400_B125","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"2021113011180097400_B126","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1440-1681.2009.05302.x","article-title":"Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors","volume":"37","author":"Huang","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2021113011180097400_B127","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"2021113011180097400_B128","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"2021113011180097400_B129","doi-asserted-by":"publisher","first-page":"C420","DOI":"10.1152\/ajpcell.00409.2004","article-title":"Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes","volume":"290","author":"Gallagher","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011180097400_B130","doi-asserted-by":"publisher","first-page":"C1169","DOI":"10.1152\/ajpcell.00145.2008","article-title":"MAP kinase\/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides","volume":"295","author":"Gallagher","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011180097400_B131","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"2021113011180097400_B132","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"2021113011180097400_B133","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijid.2020.05.002","article-title":"Urgent need for evaluating agonists of angiotensin-(1-7)\/Mas receptor axis for treating patients with COVID-19","volume":"96","author":"Shete","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"2021113011180097400_B134","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.120.047297","article-title":"Substituting angiotensin-(1-7) to prevent lung damage in SARS-CoV-2 infection?","volume":"141","author":"Peiro","year":"2020","journal-title":"Circulation"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/23\/3063\/898490\/cs-2020-0478c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/23\/3063\/898490\/cs-2020-0478c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:09:42Z","timestamp":1669939782000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/134\/23\/3063\/227110\/ACE2-in-the-renin-angiotensin-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":134,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12,11]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20200478","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12]]}}}